

Publication List Giulio Superti-Furga (Last 5 Years)

1. The TLR-independent DNA recognition pathway in murine macrophages: Ligand features and molecular signature. Karayel E, Bürckstümmer T, Weitzer S, Martinez J, Superti-Furga G. *Eur J Immunol* 2009 Jul;39(7):1929-36.
2. Target profiling of small molecules by chemical proteomics. Rix U, Superti-Furga G. *Nat Chem Biol* 2009 Sep;5(9):616-24.
3. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jäger U, Valent P. *Eur J Clin Invest* 2009 Dec;39(12):1098-109.
4. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge H, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G, *Leukemia*, 2010 Jan;24(1):44-50.
5. A biomedical adventurers' guide to navigating between careers in academia and industry. Superti-Furga G. *Nat Rev Mol Cell Biol*, 2009 Dec;10(12):884-7.
6. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Blüml S, Binder NB, Niederreiter B, Polzer K, Hayer S, Tauber S, Schett G, Scheinecker C, Kollias G, Selzer E, Bilban M, Smolen JS, Superti-Furga G, Redlich K. *Arthritis Rheum*. 2010 Jun;62(6):1608-19.
7. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G*, Koomen J*, Haura EB*. *Nat Chem Biol*. 2010 Apr;6(4):291-9.
8. A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Wojcik J, Hantschel O, Grebien F, Kaupe I, Bennett KL, Barkinge J, Jones RB, Koide A, Superti-Furga G, Koide S. *Nat Struct Mol Biol*. 2010 Apr;17(4):519-27.
9. Peroxisomes are signaling platforms for antiviral innate immunity. Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, Shum B, Hacohen N, Chen ZJ, Whelan SP, Fransen M, Nibert ML, Superti-Furga G, Kagan JC. *Cell*. 2010 May 14;141(4):668-81.
10. MASPRECTRAS 2: An integration and analysis platform for proteomic data. Mohien CU, Hartler J, Breitwieser F, Rix U, Rix LR, Winter GE, Thallinger GG, Bennett KL, Superti-Furga G, Trajanoski Z, Colinge J. *Proteomics*. 2010 Jul;10(14):2719-22.
11. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. *Blood*. 2010 Oct 28;116(17):3278-85.
12. Initial characterization of the human central proteome. Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J. *BMC Syst Biol*. 2011;5:17.
13. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, Burckstummer T, Stefanovic A, Krieger S, Bennett KL, Rulicke T, Weber F, Colinge J, Muller M, Superti-Furga G. *Nat Immunol*. 2011;12(7):624-630.
14. Proteomic analysis of human cataract aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ(R)-labelled specimens. Bennett KL, Funk M, Tschernutter M, Breitwieser FP, Planyavsky M, Ubaida Mohien C, Muller A, Trajanoski Z, Colinge J, Superti-Furga G, Schmidt-Erfurth U. *J Proteomics*. 2011;74(2):151-166.
15. Systems medicine and integrated care to combat chronic noncommunicable diseases. Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, Roca J, Agusti A, Brightling C, Cambon-Thomsen A, Cesario A, Abdelhak S, Antonarakis SE, Avignon A, Ballabio A, Baraldi E, Baranov A, Bieber T, Bockaert J,

- Brahmachari S, Brambilla C, Bringer J, Dauzat M, Ernberg I, Fabbri L, Froguel P, Galas D, Gojobori T, Hunter P, Jorgensen C, Kauffmann F, Kourilsky P, Kowalski ML, Lancet D, Pen CL, Mallet J, Mayosi B, Mercier J, Metspalu A, Nadeau JH, Ninot G, Noble D, Ozturk M, Palkonen S, Prefaut C, Rabe K, Renard E, Roberts RG, Samolinski B, Schunemann HJ, Simon HU, Soares MB, Superti-Furga G, Tegner J, Verjovski-Almeida S, Wellstead P, Wolkenhauer O, Wouters E, Balling R, Brookes AJ, Charron D, Pison C, Chen Z, Hood L, Auffray C. *Genome Med.* 2011;3(7):43.
16. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B. Winter GE, Rix U, Lissat A, Stukalov A, Mullner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G. *Mol Cancer Ther.* 2011. Mol Cancer Ther. 2011 Oct;10(10):1846-56.
 17. General statistical modeling of data from protein relative expression isobaric tags. Breitwieser FP, Muller A, Dayon L, Kocher T, Hainard A, Pichler P, Schmidt-Erfurth U, Superti-Furga G, Sanchez JC, Mechtler K, Bennett KL, Colinge J. *J Proteome Res.* 2011;10(6):2758-2766.
 18. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Huber K, Superti-Furga G. *Bioorg Med Chem.* 2011;19(12):3616-3624.
 19. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk-activation and disruption by dasatinib and bosutinib. Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hormann G, Rix U, Bennett KL, Hadzijasufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P. *Blood.* 2011;118(7):1885-98.
 20. Functional dissection of the TBK1 molecular network. Goncalves A, Buerckstuemmer T, Dixit E, Scheicher R, Górna MW, Karayel E, Sugar C, Stukalov A, Berg T, Kralovics T, Planyavsky M, Bennett KL, Colinge J, Superti-Furga G. *PLoS One* 2011;6(9):e23971
 21. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Grebien F, Hantschel O*, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiter S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G*. *Cell* 2011 Oct 14;147(2):306-19.
 22. Complement Factor H binds malondialdehyde-epitopes and protects from oxidative stress. Weismann D, Hartvigsen K, Laurer N, Bennett KL, Scholl HPN, Charbel Issa P, Cano M, Branstätter H, Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Binder CJ. *Nature* 2011, Oct 5;478(7367):76-81.
 23. Compound immobilization and drug-affinity chromatography. Rix U, Gridling M, Superti-Furga G. *Methods Mol Biol.* 2012;803:25-38.
 24. Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable". Hantschel O, Grebien F, Superti-Furga G. *Oncotarget.* 2011 Nov;2(11):828-9.
 25. Systems biology analysis of protein-drug interactions. Colinge J, Rix U, Bennett KL, Superti-Furga G. *Proteomics Clin Appl.* 2012 Jan;6(1-2):102-16.
 26. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G*, Sexl V*. *Nat Chem Biol.* 2012 Jan 29;8(3):285-93.
 27. Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression. Kachaner D, Filipe J, Laplantine E, Bauch A, Bennett KL, Superti-Furga G, Israël A, Weil R. *Mol Cell.* 2012 Feb 24;45(4):553-66.
 28. SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations. Goncalves A, Karayel E, Rice GI, Bennett KL, Crow YJ, Superti-Furga G, Bürckstümmer T. *Hum Mutat.* 2012 Jul;33(7):1116-22.
 29. A comparative proteomic study of human skin suction blister fluid from healthy individuals using immunodepletion and iTRAQ labeling. Müller AC, Breitwieser FP, Fischer H, Schuster C, Brandt O, Colinge J, Superti-Furga G, Stingl G, Elbe-Bürger A, Bennett KL. *J Proteome Res.* 2012 Jul 6;11(7):3715-27.

30. Special issue - modular protein domains. Sudol M, Cesareni G, Superti-Furga G, Just W. **FEBS Lett.** 2012 Aug 14;586(17):2571.
31. Deconvolution of targeted protein-protein interaction maps. Stukalov A, Superti-Furga G, Colinge J. **J Proteome Res.** 2012 Aug 3;11(8):4102-9.
32. Viral immune modulators perturb the human molecular network by common and unique strategies. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M, Stefanovic A, Eberle CA, Goncalves A, Bürckstümmer T, Müller AC, Fauster A, Holze C, Lindsten K, Goodbourn S, Kochs G, Weber F, Bartenschlager R, Bowie AG, Bennett KL, Colinge J, Superti-Furga G. **Nature.** 2012 Jul 26;487(7408):486-90.
33. Mig6 Is a Sensor of EGF Receptor Inactivation that Directly Activates c-Abl to Induce Apoptosis during Epithelial Homeostasis. Hopkins S, Linderoth E, Hantschel O, Suarez-Henriques P, Pilia G, Kendrick H, Smalley MJ, Superti-Furga G, Ferby I. **Dev Cell.** 2012 Sep 11;23(3):547-59.
34. The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL. Hantschel O*, Grebien F, Superti-Furga G*. **Cancer Res.** 2012 Oct 1;72(19):4890-5.
35. Systems-pharmacology dissection of a drug synergy in imatinib resistant CML. Winter GE, Rix E, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. **Nat Chem Biol** 2012 Nov;8(11):905-12.
36. A method to resolve the composition of heterogeneous affinity-purified protein complexes assembled around a common protein by chemical cross-linking, gel electrophoresis and mass spectrometry. Rudashevskaya EL, Sacco R, Kratochwill K, Huber ML, Gstaiger M, Superti-Furga G, Bennett KL. **Nat Protoc.** 2013 Jan;8(1):75-97.
37. Structural basis for 5'-triphosphate viral RNA recognition by human IFIT proteins. Abbas YM, Pichlmair A, Górna MW, Superti-Furga G*, Nagar B*, **Nature** 2013 Feb 7;494(7435):60-4.
38. Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Varjosalo M, Sacco R, Stukalov A, van Droogen A, Planyavsky M, Hauri S, Aebersold R, Bennett KL, Colinge J, Gstaiger M*, Superti-Furga G*. **Nat Methods.** 2013 Apr;10(4):307-14.
39. FAM111A Mutations Result in Hypoparathyroidism and Impaired Skeletal Development. Unger S, Górna MW, Le Béhec A, Do Vale-Pereira S, Bedeschi MF, Geiberger S, Grigelioniene G, Horemuzova E, Lalatta F, Lausch E, Magnani C, Nampoothiri S, Nishimura G, Petrella D, Rojas-Ringeling F, Utsunomiya A, Zabel B, Pradervand S, Harshman K, Campos-Xavier B, Bonafé L, Superti-Furga G, Stevenson B, Superti-Furga A. **Am J Hum Genet.** 2013 Jun 6;92(6):990-5.
40. A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Borgdorff V, Rix U, Winter GE, Gridling M, Müller AC, Breitwieser FP, Wagner C, Colinge J, Bennett KL, Superti-Furga G, Wagner SN. **Oncogene.** 2013 Jun 3. doi: 10.1038/onc.2013.185.
41. Protein interaction networks in innate immunity. Rebsamen M, Kandasamy RK, Superti-Furga G. **Trends Immunol.** 2013 Dec;34(12):610-9.
42. Experimental characterization of the human non-sequence-specific nucleic acid interactome. Duernberger G, Burckstummer T, Huber K, Giambruno R, Doerks T, Karayel E, Burkard TR, Kaupe I, Muller AC, Schonegger A, Ecker GF, Lohninger H, Bork P, Bennett KL, Superti-Furga G, Colinge J. **Genome Biol.** 2013 Jul 31;14(7):R81.
43. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. Mellacheruvu D, Wright Z, Couzens AL, Lambert JP, St-Denis NA, Li T, Miteva YV, Hauri S, Sardiou ME, Low TY, Halim VA, Bagshaw RD, Hubner NC, Al-Hakim A, Bouchard A, Faubert D, Fermin D, Dunham WH, Goudreault M, Lin ZY, Badillo BG, Pawson T, Durocher D, Coulombe B, Aebersold R, Superti-Furga G, Colinge J, Heck AJ, Choi H, Gstaiger M, Mohammed S, Cristea IM, Bennett KL, Washburn MP, Raught B, Ewing RM, Gingras AC, Nesvizhskii AI. **Nat Methods.** 2013 Aug;10(8):730-6.

44. A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. Chamrád I, Rix U, Stukalov A, Gridling M, Parapatics K, Müller AC, Altiock S, Colinge J, Superti-Furga G, Haura EB, Bennett KL. **J Proteome Res.** 2013 Sep 6;12(9):4005-17.
45. Affinity Purification Strategies for Proteomic Analysis of Transcription Factor Complexes. Giamb Bruno R, Grebien F, Stukalov A, Knoll C, Planyavsky M, Rudashevskaya EL, Colinge J, Superti-Furga G, Bennett KL. **J Proteome Res.** 2013 September 6; 12(9): 4018–4027.
46. A reversible gene trap collection empowers haploid genetics in human cells. Bürckstümmer T*, Banning C, Hainzl P, Schobesberger R, Kerzendorfer C, Pauler FM, Chen D, Them N, Schischlik F, Rebsamen M, Smida M, Fece de la Cruz F, Lapao A, Liszt M, Eizinger B, Guenzl PM, Blomen VA, Konopka T, Gapp B, Parapatics K, Maier B, Stöckl J, Fischl W, Salic S, Taba R, Knapp S, Bennett KL, Bock C, Colinge J, Kralovics R, Ammerer G, Casari G, Brummelkamp TR*, Superti-Furga G* & SM Nijman*. **Nat Methods.** 2013 Oct;10(10):965-71., covered in *Nature* as highlight.
47. A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL. Rix U, Colinge J, Blatt K, Gridling M, Rensing Rix LL, Parapatics K, Cerny-Reiterer S, Burkard TR, Jäger U, Melo J, Bennett KL, Valent P, Superti-Furga G. **PLoS One.** 2013; 8(10): e77155.
48. Viperin is an iron-sulfur protein that inhibits genome synthesis of tick-borne encephalitis virus via radical SAM domain activity. Upadhyay AS, Vonderstein K, Pichlmair A, Stehling O, Bennett KL, Dobler G, Guo JT, Superti-Furga G, Lill R, Overby AK, Weber F. **Cell Microbiol.** 2013 Nov 19.
49. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. **Mol Syst Biol.** 2013 Nov 5;9:705.
50. Somatic mutations of calreticulin in myeloproliferative neoplasms. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanese C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R. **N Engl J Med.** 2013 Dec 19;369(25):2379-90.
51. Interactome of two diverse RNA granules links mRNA localization to translational repression in neurons. Fritzsche R, Karra D, Bennett KL, Ang FY, Heraud-Farlow JE, Tolino M, Doyle M, Bauer KE, Thomas S, Planyavsky M, Arn E, Bakosova A, Jungwirth K, Hörmann A, Palfi Z, Sandholzer J, Schwarz M, Macchi P, Colinge J, Superti-Furga G, Kiebler MA. **Cell Rep.** 2013 Dec 26;5(6):1749-62.
52. Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Liehl P, Zuzarte-Luís V, Chan J, Zillinger T, Baptista F, Carapau D, Konert M, Hanson KK, Carret C, Lassnig C, Müller M, Kalinke U, Saeed M, Chora AF, Golenbock DT, Strobl B, Prudêncio M, Coelho LP, Kappe SH, Superti-Furga G, Pichlmair A, Vigário AM, Rice CM, Fitzgerald KA, Barchet W, Mota MM. **Nat Med.** 2014 Jan;20(1):47-53.
53. Virulence Factor NSs of Rift Valley Fever Virus Recruits the F-Box Protein FBXO3 To Degrade Subunit p62 of General Transcription Factor TFIIH. Kainulainen M, Habjan M, Hubel P, Busch L, Lau S, Colinge J, Superti-Furga G, Pichlmair A, Weber F. **J Virol.** 2014 Mar;88(6):3464-73.
54. A1.8 A dual role of MTOR in the rheumatoid mesenchymal tissue response to inflammation. Karonitsch T, Dalwigk K, Holinka J, Niederreiter B, Steiner CW, Bilban M, Wanivenhaus A, Windhager R, Smolen JS, Kiener HP, Superti-Furga G. **Ann Rheum Dis,** 2014 Mar 1;73 Suppl 1:A3-4.
55. MMP13 mutations are the cause of recessive metaphyseal dysplasia, Spahr type. Bonafé L, Liang J, Gorna MW, Zhang Q, Ha-Vinh R, Campos-Xavier AB, Unger S, Beckmann JS, Le Béchech A, Stevenson B, Giedion A, Liu X, Superti-Furga G, Wang W, Spahr A, Superti-Furga A. **Am J Med Genet A,** 2014 Mar 19. doi: 10.1002/ajmg.a.36431. [Epub ahead of print]
56. IFITs: Emerging Roles as Key Anti-Viral Proteins. Vladimer GI, Gorna MW, Superti-Furga G. **Front Immunol,** 2014 Mar 10;5:94.

57. Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy. Huber KVM, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Gokturk C, Sanjiv K, Strömberg K, Pham T, Warpman Berglund U, Colinge J, Bennett KL, Loizou J, Helleday T, Knapp S, Superti-Furga G. **Nature**, 2014 Apr 10;508(7495):222-7.
58. Building and exploring an integrated human kinase network: Global organization and medical entry points. Colinge J, César-Razquin A, Huber K, Breitwieser FP, Májek P, Superti-Furga G. **J Proteomics**. 2014 Apr 3. pii: S1874-3919(14)00150-X.
59. Evaluating the Promiscuous Nature of Tyrosine Kinase Inhibitors Assessed in A431 Epidermoid Carcinoma Cells by Both Chemical- and Phosphoproteomics. Giansanti P, Preisinger C, Huber KV, Gridling M, Superti-Furga G, Bennett KL, Heck AJ. **ACS Chem Biol**. 2014 Jul 18;9(7):1490-8.
60. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Winter G, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, Huber KVM, Gridling M, Chen D, Klampfl T, Kralovics R, Kubicek S, Fernandez-Capetillo O, Brummelkamp TR, Superti-Furga G. **Nat Chem Biol**. 2014 Sep;10(9):768-73.
61. The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production. Eberle CA, Zayas M, Stukalov A, Pichlmair A, Alvisi G, Müller AC, Bennett KL, Bartenschlager R, Superti-Furga G. **Virology**. 2014 Aug;462-463:34-41.
62. Toward effective sharing of high-dimensional immunology data. Snijder B, Kandasamy RK, Superti-Furga G. **Nat Biotechnol**. 2014 Aug 7;32(8):755-9.
63. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Boztug K, Järvinen PM, Salzer E, Racek T, Mönch S, Garncarz W, Gertz EM, Schäffer AA, Antonopoulos A, Haslam SM, Schieck L, Puchałka J, Diestelhorst J, Appaswamy G, Lescoeur B, Giambruno R, Bigenzahn JW, Elling U, Pfeifer D, Conde CD, Albert MH, Welte K, Brandes G, Sherkat R, van der Werff Ten Bosch J, Rezaei N, Etzioni A, Bellanné-Chantelot C, Superti-Furga G, Penninger JM, Bennett KL, von Blume J, Dell A, Donadieu J, Klein C. **Nat Genet**. 2014 Sep;46(9):1021-7.

10 Most Important Scientific Publications Giulio Superti-Furga

1. Functional organization of a eukaryotic proteome: systematic analysis of multi-protein complexes in *Saccharomyces cerevisiae*. Gavin, A.C., Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM, Remor M, Hofert C, Schelder M, Brajenovic M, Ruffner H, Merino A, Klein K, Hudak M, Dickson D, Rudi T, Gnau V, Bauch A, Bastuck S, Huhse B, Leutwein C, Heurtier MA, Copley RR, Edlmann A, Querfurth E, Rybin V, Drewes G, Raida M, Bouwmeester T, Bork P, Seraphin B, Kuster B, Neubauer G, Superti-Furga G. **Nature** 2002 415, 141-147. .
2. A physical and functional map of the TNF α /NF κ B signalling pathway. Bouwmeester T*, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari, G, Drewes G, Gavin AC, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, and Superti-Furga G*. **Nature Cell Biology** 2004 6:97-105.
3. Proteome survey reveals modularity of the yeast cell machinery. Gavin AC, Aloy, P, Grandi P, Krause R, Boesche M, Marzioch M, Rau C, Jensen LJ, Bastuck S, Dümplefeld B, Edlmann A, Heurtier MA, Hoffmann V, Hoefert C, Michon M, Schirle M, Remor M, Bauer A, Bouwmeester T, Casari G, Drewes, G, Neubauer G, Rick JM, Kuster B, Bork P, Russell RB*, Superti-Furga G*. **Nature** 2006 440(7084):631-6.
4. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Bürckstümmer T, Baumann C, Blüml S, Dixit E, Dürnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, Superti-Furga G. **Nat Immunol** 2009 Mar;10(3):266-72.

5. IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, Burckstummer T, Stefanovic A, Krieger S, Bennett KL, Rulicke T, Weber F, Colinge J, Muller M, Superti-Furga G. *Nat Immunol* 2011;12(7):624-630.
6. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Grebien F, Hantschel O, Wojcik J, Kaupe I, Kovacic B, Wyrzucki AM, Gish GD, Cerny-Reiter S, Koide A, Beug H, Pawson T, Valent P, Koide S, Superti-Furga G. *Cell* 2011, Oct 14;147(2):306-19.
7. Viral immune modulators perturb the human molecular network by common and unique strategies. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M, Stefanovic A, Eberle CA, Goncalves A, Bürckstümmer T, Müller AC, Fauster A, Holze C, Lindsten K, Goodbourn S, Kochs G, Weber F, Bartenschlager R, Bowie AG, Bennett KL, Colinge J, Superti-Furga G. *Nature*. 2012 Jul 26;487(7408):486-90.
8. Systems-pharmacology dissection of a drug synergy in imatinib resistant CML. Winter GE, Rix E, Carlson SM, Gleixner KV, Grebien F, Gridling M, Müller AC, Breitwieser FP, Bilban M, Colinge J, Valent P, Bennett KL, White FM, Superti-Furga G. *Nat Chem Biol* 2012, 8(11):905-12.
9. Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy. Huber KVM, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Gokturk C, Sanjiv K, Strömberg K, Pham T, Warpman Berglund U, Colinge J, Bennett KL, Loizou J, Helleday T, Knapp S, Superti-Furga G. *Nature*, 2014 Apr 10;508(7495):222-7.
10. The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity. Winter G, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, Huber KVM, Gridling M, Chen D, Klampfl T, Kralovics R, Kubicek S, Fernandez-Capetillo O, Brummelkamp TR, Superti-Furga G. *Nat Chem Biol*. 2014 Sep;10(9):768-73.